13314-97-1

Basic information

• Product Name: 1-(morpholin-4-ylmethyl)pyrrolidine-2,5-dione
• Synonyms: 1-(Morpholin-4-ylmethyl)pyrrolidine-2,5-dione; 2,5-pyrrolidinedione, 1-(4-morpholinylmethyl)-
• CAS NO: 13314-97-1
• Molecular Formula: C₉H₁₄N₂O₃
• Molecular Weight: 198.2191
• Mol File: 13314-97-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 382.6°C at 760 mmHg
• Flash Point: 185.2°C
• Density: 1.279g/cm³
• Vapor Pressure: 4.66E-06mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: 1-(morpholin-4-ylmethyl)pyrrolidine-2,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(morpholin-4-ylmethyl)pyrrolidine-2,5-dione(13314-97-1)
• EPA Substance Registry System: 1-(morpholin-4-ylmethyl)pyrrolidine-2,5-dione(13314-97-1)

Safety Data

• Hazardous Substances Data: 13314-97-1(Hazardous Substances Data)

Usage

General Description

1-(morpholin-4-ylmethyl)pyrrolidine-2,5-dione is a chemical compound with a complex structure that includes a pyrrolidine ring and a morpholine ring. It is used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical compounds. It has the potential to exhibit biological activity due to its structural features, making it a valuable starting material for the development of drug candidates. Additionally, it has been studied for its potential as a corrosion inhibitor for metal surfaces. Overall, 1-(morpholin-4-ylmethyl)pyrrolidine-2,5-dione is a versatile compound with potential applications in the pharmaceutical and material science industries.

Upstream product

• 4432-43-3 N-hydroxymethylmorpholine 
• 123-56-8 Succinimide 
• 110-91-8 morpholine 
• 50-00-0 formaldehyd 

Relevant articles and documents

Synthesis, molecular structure, quantum chemical analysis, spectroscopic and molecular docking studies of N-(Morpholinomethyl) succinimide using DFT method

N-(Morpholinomethyl) succinimide (SMF) bearing the empirical formula C9H14N2O3, has been synthesized by using the mannich condensation reaction. On considering its extensive pharmaceutical usage and medicinal value, we investigated its chemical structure and composition by employing various spectral techniques like 1H, 13C NMR, UV-Visible spectroscopy, FT-IR, FT-Raman and TG/DSC techniques. Density Functional Theory (DFT) computation was adopted to study the electronic structure of the SMF molecule. Incorporating the VEDA 4 package, Total Energy Distribution (TED) was computed for vibrational assignment. In order to find out the strength and stability of the molecules an analysis based on the Natural Bond Orbital (NBO) was carried out. Gauge-Independent Atomic orbital (GIAO) was employed to confirm whether the 1H and 13C NMR spectrum could show the chemical shift values. Frontier molecular orbitals in order to investigate the forbidden energy gap, viz., HOMO-LUMO were calculated and the λmax values were observed. Frontier molecular orbitals were mainly identified which contributed the atomic orbitals. Based on the chemical activity, mapping of the figure was carried out on molecular electrostatic potential. The nature of molecular interaction was ascertained for molecular docking studies in which the biological protein system was reported. Based on the results, a suitable mechanism, its protein binding mode and drug action were presented. Molecular docking results suggested that the SMF molecule might exhibit inhibitory activity against the lung cancer protein.

Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs

The aim of this paper was to describe the synthesis of a library of 28 new 1,3-substituted pyrrolidine-2,5-dione as potential anticonvulsant agents. The anticonvulsant activity was evaluated using three acute models of seizures in mice (MES-maximal electroshock, scPTZ-subcutaneous pentylenetetrazole, and 6?Hz-psychomotor seizure tests). The neurotoxicity was determined by rotarod test. The most promising compound was found to be N-[{morpholin-1-yl}-methyl]-3-benzhydryl-pyrrolidine-2,5-dione (15), as it was active in the MES (ED50?=?41.0?mg/kg), scPTZ (ED50?=?101.6?kg/mg), and 6?Hz (ED50?=?45.42?mg/kg) tests. This compound displayed more beneficial protection index (PI) than antiepileptic drugs such as ethosuximide, lacosamide and valproic acid. In vitro studies for compound 15 were conducted and provided information that its possible mechanism of action is related to blocking of the neuronal voltage-sensitive sodium (site 2) and L-type calcium channels.